Personalized briefing
Discovery of the day · Neurology
[Series] Fluid biomarkers in the evolving care landscape of Alzheimer’s disease and related disorders
Dear Kelly M Leyden, this is your personalized scientific intelligence briefing — curated for your work in Neurology.
Key finding
Medicine · Neurology
Discovery of the day
Ultrasensitive immunoassay platforms and high-specificity antibodies have enabled blood-based biomarkers — notably neurofilament light for frontotemporal dementia and amyotrophic lateral sclerosis, and phosphorylated tau 217 for Alzheimer’s disease — to move from research into routine clinical practice. These assays demonstrate sufficient diagnostic specificity to support implementation at the point of care, arriving in parallel with the expanding clinical availability of amyloid-targeting therapeutics for Alzheimer’s disease. For your work on blood-based proteomic biomarkers of disease activity in neurodegenerative disease, this signals that plasma p-tau 217 and NfL are now validated for diagnostic assay deployment and should be correlated with imaging, clinical scales, and sensor-derived measures to establish their utility for longitudinal progression monitoring.
Novelty
76%
Rigor
88%
Significance
92%
Validity
85%
Clarity
91%
Advertisement
GroupRFQ — join group deals on lab & medical equipment. Pool orders, unlock volume pricing. See open deals →
Your briefing is personalized based on your selected fields, keywords, and research interests.
